<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Brain</journal-id><journal-id journal-id-type="publisher-id">brainj</journal-id><journal-id journal-id-type="hwp">brain</journal-id><journal-title-group><journal-title>Brain</journal-title></journal-title-group><issn pub-type="ppub">0006-8950</issn><issn pub-type="epub">1460-2156</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1093/brain/awp158</article-id><article-id pub-id-type="publisher-id">awp158</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Gene&#x02013;environment interactions in Leber hereditary optic neuropathy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kirkman</surname><given-names>Matthew Anthony</given-names></name><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yu-Wai-Man</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref><xref ref-type="aff" rid="AFF2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Korsten</surname><given-names>Alex</given-names></name><xref ref-type="aff" rid="AFF3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Leonhardt</surname><given-names>Miriam</given-names></name><xref ref-type="aff" rid="AFF4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dimitriadis</surname><given-names>Konstantin</given-names></name><xref ref-type="aff" rid="AFF4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>De Coo</surname><given-names>Ireneaus F.</given-names></name><xref ref-type="aff" rid="AFF3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Klopstock</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="AFF4"><sup>4</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chinnery</surname><given-names>Patrick Francis</given-names></name><xref ref-type="aff" rid="AFF1"><sup>1</sup></xref></contrib></contrib-group><aff id="AFF1">1 Mitochondrial Research Group, Institute for Ageing and Health, The Medical School, Newcastle University, UK</aff><aff id="AFF2">2 Department of Ophthalmology, Royal Victoria Infirmary, Newcastle upon Tyne, UK</aff><aff id="AFF3">3 Department of Child Neurology, Erasmus Medical Center, University Medical Center Rotterdam, The Netherlands</aff><aff id="AFF4">4 Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University, Munich, Germany</aff><author-notes><corresp>Correspondence to: Prof. Patrick Francis Chinnery, Mitochondrial Research Group, The Medical School, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK E-mail: <email>P.F.Chinnery@ncl.ac.uk</email></corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>12</day><month>6</month><year>2009</year></pub-date><pub-date pub-type="pmc-release"><day>12</day><month>6</month><year>2009</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>132</volume><issue>9</issue><fpage>2317</fpage><lpage>2326</lpage><history><date date-type="received"><day>15</day><month>2</month><year>2009</year></date><date date-type="rev-recd"><day>10</day><month>5</month><year>2009</year></date><date date-type="accepted"><day>11</day><month>5</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; 2009 The Author(s)</copyright-statement><copyright-year>2009</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/uk/"><license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/uk/">http://creativecommons.org/licenses/by-nc/2.0/uk/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Leber hereditary optic neuropathy (LHON) is a genetic disorder primarily due to mutations of mitochondrial DNA (mtDNA). Environmental factors are thought to precipitate the visual failure and explain the marked incomplete penetrance of LHON, but previous small studies have failed to confirm this to be the case. LHON has no treatment, so identifying environmental triggers is the key to disease prevention, whilst potentially revealing new mechanisms amenable to therapeutic manipulation. To address this issue, we conducted a large, multicentre epidemiological study of 196 affected and 206 unaffected carriers from 125 LHON pedigrees known to harbour one of the three primary pathogenic mtDNA mutations: m.3460G&#x0003e;A, m.11778G&#x0003e;A and m.14484T&#x0003e;C. A comprehensive history of exposure to smoking, alcohol and other putative environmental insults was collected using a structured questionnaire. We identified a strong and consistent association between visual loss and smoking, independent of gender and alcohol intake, leading to a clinical penetrance of 93% in men who smoked. There was a trend towards increased visual failure with alcohol, but only with a heavy intake. Based on these findings, asymptomatic carriers of a LHON mtDNA mutation should be strongly advised not to smoke and to moderate their alcohol intake.</p></abstract><kwd-group><kwd>Leber hereditary optic neuropathy</kwd><kwd>mitochondrial DNA</kwd><kwd>alcohol</kwd><kwd>tobacco</kwd><kwd>epigenetics</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Leber hereditary optic neuropathy (LHON, MIM 535000) is a mitochondrial genetic disease that preferentially affects young adults in their second and third decades of life, with over 95% of cases arising due to one of three point mutations in the mitochondrial genome: m.3460G&#x0003e;A, m.11778G&#x0003e;A and m.14484T&#x0003e;C (Harding <italic>et al</italic>., <xref ref-type="bibr" rid="B11">1995</xref>; Mackey <italic>et al</italic>., <xref ref-type="bibr" rid="B19">1996</xref>; Man <italic>et al</italic>., <xref ref-type="bibr" rid="B21">2002</xref>; Newman and Biousse, <xref ref-type="bibr" rid="B22">2004</xref>; Yu-Wai-Man <italic>et al</italic>., <xref ref-type="bibr" rid="B39">2009</xref>). LHON is a common cause of inherited visual failure, with a minimum prevalence of 1 in 30 000 in Northern Europe, and with an estimated mutation carrier rate of &#x0223c;1 in 350 (Man <italic>et al</italic>., <xref ref-type="bibr" rid="B20">2003</xref>; Spruijt <italic>et al</italic>., <xref ref-type="bibr" rid="B35">2006</xref>; Elliott <italic>et al</italic>., <xref ref-type="bibr" rid="B8">2008</xref>). Clinically, LHON is characterized by bilateral sub-acute loss of central vision as a result of focal degeneration of the retinal ganglion cell layer within the papillomacular bundle (Yu-Wai-Man <italic>et al</italic>., <xref ref-type="bibr" rid="B39">2009</xref>). The visual prognosis is poor and the majority of patients remain severely visually impaired secondary to the marked reduction in visual acuity and the dense scotoma in their visual fields.</p><p>LHON shows marked incomplete penetrance with only &#x0223c;50% of male and &#x0223c;10% of female carriers developing the optic neuropathy in their lifetime (Seedorff, <xref ref-type="bibr" rid="B31">1985</xref>; Brown and Wallace, <xref ref-type="bibr" rid="B3">1994</xref>; Nikoskelainen, <xref ref-type="bibr" rid="B24">1994</xref>). The secondary factors modulating the mitochondrial DNA (mtDNA) LHON mutations still remain largely undefined, although the gender bias has been linked to the synergistic influence of visual-loss susceptibility loci on the X-chromosome (Hudson <italic>et al</italic>., <xref ref-type="bibr" rid="B13">2005</xref>; Shankar <italic>et al</italic>., <xref ref-type="bibr" rid="B32">2008</xref>). Genetic factors, however, cannot provide a complete explanation for the reduced penetrance. Five pairs of monozygotic twins with a primary LHON mutation have been identified in the literature (Nikoskelainen <italic>et al</italic>., <xref ref-type="bibr" rid="B25">1987</xref>; Newman <italic>et al</italic>., <xref ref-type="bibr" rid="B23">1991</xref>; Johns <italic>et al</italic>., <xref ref-type="bibr" rid="B15">1993</xref>; Harding <italic>et al</italic>., <xref ref-type="bibr" rid="B11">1995</xref>; Biousse <italic>et al</italic>., <xref ref-type="bibr" rid="B1">1997</xref>; Lam, <xref ref-type="bibr" rid="B17">1998</xref>) and among two pairs, one sibling has remained visually unaffected on long-term follow-up (Johns <italic>et al</italic>., <xref ref-type="bibr" rid="B15">1993</xref>; Biousse <italic>et al</italic>., <xref ref-type="bibr" rid="B1">1997</xref>). Whilst it is possible that the unaffected sibling will lose vision in later life, this discordance supports the role of environmental factors in triggering visual loss among at-risk carriers. LHON is therefore likely to be a complex multifactorial disease, with environmental triggers operating at the individual level contributing to the observed intra- and inter-familial variability in penetrance.</p><p>A limited number of relatively small case&#x02013;control studies have attempted to address this important issue, some of which suggest an increased risk of visual loss among LHON carriers with high alcohol and tobacco consumption (Cullom <italic>et al</italic>., <xref ref-type="bibr" rid="B6">1993</xref>; Golnik and Shaible, <xref ref-type="bibr" rid="B9">1994</xref>; Riordan-Eva <italic>et al</italic>., <xref ref-type="bibr" rid="B27">1995</xref>; Chalmers and Harding, <xref ref-type="bibr" rid="B5">1996</xref>; Tsao <italic>et al</italic>., <xref ref-type="bibr" rid="B37">1999</xref>; Sadun <italic>et al</italic>., <xref ref-type="bibr" rid="B29">2003</xref>). However, the largest study to date involving affected and unaffected siblings from 80 LHON sibships found no relationship between smoking or alcohol and the likelihood of visual failure (Kerrison <italic>et al</italic>., <xref ref-type="bibr" rid="B16">2000</xref>). There are also anecdotal reports of trauma, nutritional deprivation, metabolic disturbance, exposure to industrial toxins, anti-retroviral drugs, psychological stress or acute illness precipitating the onset of blindness in LHON, but the strength of the causal relationship is difficult to establish (DuBios and Feldon, <xref ref-type="bibr" rid="B7">1992</xref>; Johns <italic>et al</italic>., <xref ref-type="bibr" rid="B15">1993</xref>; Hwang and Park, <xref ref-type="bibr" rid="B14">1996</xref>; Mackey <italic>et al</italic>., <xref ref-type="bibr" rid="B18">2003</xref>; Sadun <italic>et al</italic>., <xref ref-type="bibr" rid="B29">2003</xref>; Sanchez <italic>et al</italic>., <xref ref-type="bibr" rid="B30">2006</xref>; Carelli <italic>et al</italic>., <xref ref-type="bibr" rid="B4">2007</xref>).</p><p>There is currently no proven treatment in LHON that will either prevent disease conversion or improve visual prognosis following the onset of optic neuropathy. The identification of potentially modifiable risk factors would therefore contribute significantly to counselling these families, and reveal potential disease mechanisms. To address this issue we carried out the largest multi-centre study of potential environmental triggers in 402 LHON mtDNA mutation carriers.</p></sec><sec sec-type="subjects|methods"><title>Subjects and Methods</title><sec sec-type="subjects"><title>Subjects</title><p>A structured questionnaire was conducted on 196 affected and 206 unaffected carriers (<italic>n</italic> = 402) from 125 genealogically distinct LHON pedigrees in three centres: Newcastle, UK (<italic>n</italic> = 47); Rotterdam, the Netherlands (<italic>n</italic> = 46); and Munich, Germany (<italic>n</italic> = 32). All LHON carriers were homoplasmic for one of the three primary mtDNA mutations: m.3460G&#x0003e;A (<italic>n</italic> = 71), m.11778G&#x0003e;A (<italic>n</italic> = 270) and m.14484T&#x0003e;C (<italic>n</italic> = 61), confirmed by mtDNA sequencing, restriction fragment length polymorphism analysis or primer extension assay. With the exception of one Asian individual, all participants were of white Caucasian origin. As well as having ethical approval, this study complied with the Declaration of Helsinki.</p></sec><sec><title>Data collection</title><p>Participants were interviewed via telephone by three investigators (MAK, AK and ML) using a standardized questionnaire that has been adapted from previous studies (Tsao <italic>et al</italic>., <xref ref-type="bibr" rid="B37">1999</xref>; Kerrison <italic>et al</italic>., <xref ref-type="bibr" rid="B16">2000</xref>) (<ext-link ext-link-type="uri" xlink:href="http://brain.oxfordjournals.org/cgi/content/full/awp158/DC1">Supplementary data</ext-link>). The dataset collected included basic demographic details, affected status, age of onset (time at which first symptoms were noted), time course and progression of visual loss, and a detailed account of exposure to possible environmental triggers to allow a quantitative analysis where applicable. The lifestyle factors specifically queried were (i) smoking, (ii) alcohol, (iii) trauma, (iv) recreational drugs, (v) occupational and industrial toxin exposure, (vi) diet, (vii) physical exercise, (viii) medication history including vitamins and herbal remedies and (ix) any relevant medical comorbidity. Consumption of alcoholic beverages (beer, wine, liquor and alcopops) among subjects was combined and converted to standardized units of alcohol as outlined by the UK Office for National Statistics (Office for National Statistics, <xref ref-type="bibr" rid="B26">2007</xref>). Cumulative consumption of alcohol was measured as &#x02018;drink years&#x02019;, which was calculated by the units of alcohol per week multiplied by the number of years of drinking, taking into account the variations in levels of consumption as identified through the questionnaire. Maximum intensity of alcohol consumption was quantified as the maximum units of alcohol consumed in a single week. In line with a previous study (Kerrison <italic>et al</italic>., <xref ref-type="bibr" rid="B16">2000</xref>), cumulative consumption and maximum intensity were analysed as both continuous variables and categorical variables by creating three subject groups: (i) non-drinkers, (ii) those drinking &#x0003c;75th percentile (light drinking) and (iii) those drinking &#x02265;75th percentile (heavy drinking), using the level of alcohol consumption among unaffected LHON carriers to define the reference percentile ranges. Affected LHON carriers who only began drinking after losing vision had an alcohol exposure of zero and for those who started drinking beforehand, only their consumption (cumulative and maximum intensity) up to the onset of visual loss was considered for the purposes of statistical analysis. A similar analysis protocol was applied to smoking, with cumulative smoking expressed in terms of &#x02018;pack years&#x02019;, calculated by multiplying the number of packs of cigarettes smoked per day by the number of years of smoking, and maximum intensity of smoking quantified in terms of the maximum number of cigarettes consumed in a single day.</p></sec><sec><title>Statistical analysis</title><p>Statistical analyses were performed using SPSS&#x02122; v.15 statistical software (Chicago, IL, USA). Survival analysis was carried out by constructing Kaplan&#x02013;Meier survival curves plotted against age, gender and the specific LHON mutation and including censored cases i.e. unaffected individuals who, at the time of interview, had not lost vision. Binary logistic regression was used to determine which variables in our dataset influenced the risk of visual loss among LHON carriers. This form of analysis assumes that the logarithm of the odds ratio is a linear function of the predictor variables included in the model: <disp-formula><graphic xlink:href="awp158um1"/></disp-formula> where <italic>P</italic> is the probability of a LHON carrier converting to affected disease status; <italic>X</italic><sub>1</sub>, <italic>X</italic><sub>2</sub> &#x02026; <italic>X<sub>n</sub></italic> represent the chosen predictor variables; and <italic>B</italic><sub>0</sub>, <italic>B</italic><sub>1</sub>, &#x02026; <italic>B<sub>n</sub></italic> are coefficients reflecting the nature of each predictor (Bland, <xref ref-type="bibr" rid="B2">2000</xref>). Visual failure was the dependent response variable used in the model, with the following as independent variables: (i) age, (ii) gender, (iii) LHON mutation (m.11778G&#x0003e;A, m.3460G&#x0003e;A, m.14484T&#x0003e;C), (iv) cumulative consumption of tobacco and alcohol and (v) maximum intensity of tobacco and alcohol consumption. Categorical smoking and alcohol data incorporated into the model was based on the 75th percentiles for the unaffected LHON carrier group.</p></sec></sec><sec sec-type="results"><title>Results</title><p>The mean age at onset of visual loss in the affected individuals was 27.9 years (SD = 14.9), with a mean disease duration of 15.5 years (SD = 15.4) (<xref ref-type="table" rid="T1">Table 1</xref>). In a minority of affected carriers, visual failure occurred before the age of 10 years (<italic>n</italic> = 15, 7.7%) and after the age of 50 years (<italic>n</italic> = 18, 9.2%). There was no difference in the age of onset of visual loss among the three primary LHON mutations (Kaplan&#x02013;Meier, log rank <italic>P</italic> = 0.946) (<xref ref-type="fig" rid="F1">Fig. 1</xref>). Among the affected group, 74.5% were male, with a male to female ratio of 2.9:1 and male gender was a significant risk factor for visual loss [Odds ratio (OR) = 7.11, 95% confidence interval (CI) = 4.58&#x02013;11.03, <italic>P</italic> &#x0003c; 0.001] (<xref ref-type="fig" rid="F2">Fig. 2</xref>). <fig id="F1" position="float"><label>Figure 1</label><caption><p>Kaplan&#x02013;Meier curve showing disease onset with regard to the three primary LHON mutations (<italic>P</italic> = 0.946 by log-rank test). Age of onset (years) was defined as the age when the patients first noticed their visual symptoms.</p></caption><graphic xlink:href="awp158f1"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>Kaplan&#x02013;Meier curve of disease onset for male and female LHON carriers (<italic>P</italic> &#x0003c; 0.001 by log-rank test).</p></caption><graphic xlink:href="awp158f2"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Characteristics of the study population</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Affected</th><th rowspan="1" colspan="1">Unaffected</th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1">Number of individuals</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;m.11778G&#x0003e;A (%)</td><td rowspan="1" colspan="1">132 (67.3)</td><td rowspan="1" colspan="1">138 (67.0)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;m.3460G&#x0003e;A (%)</td><td rowspan="1" colspan="1">35 (17.9)</td><td rowspan="1" colspan="1">36 (17.5)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;m.14484T&#x0003e;C (%)</td><td rowspan="1" colspan="1">29 (14.8)</td><td rowspan="1" colspan="1">32 (15.5)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Total</td><td rowspan="1" colspan="1">196</td><td rowspan="1" colspan="1">206</td></tr><tr><td rowspan="1" colspan="1">Sex, <italic>N</italic> (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Male</td><td rowspan="1" colspan="1">146 (74.5)</td><td rowspan="1" colspan="1">60 (29.1)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Female</td><td rowspan="1" colspan="1">50 (25.5)</td><td rowspan="1" colspan="1">146 (70.9)</td></tr><tr><td rowspan="1" colspan="1">Male: female ratio</td><td rowspan="1" colspan="1">2.9</td><td rowspan="1" colspan="1">0.4</td></tr><tr><td rowspan="1" colspan="1">Age at time of study (years)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Mean (SD)</td><td rowspan="1" colspan="1">43.3 (16.9)</td><td rowspan="1" colspan="1">47.8 (14.9)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Range</td><td rowspan="1" colspan="1">13&#x02013;82</td><td rowspan="1" colspan="1">14&#x02013;83</td></tr><tr><td rowspan="1" colspan="1">Numbers of tobacco smokers (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Male</td><td rowspan="1" colspan="1">107 (73.3)</td><td rowspan="1" colspan="1">33 (55.0)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Female</td><td rowspan="1" colspan="1">27 (54.0)</td><td rowspan="1" colspan="1">75 (51.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Whole group</td><td rowspan="1" colspan="1">134 (68.4)</td><td rowspan="1" colspan="1">108 (52.4)</td></tr><tr><td rowspan="1" colspan="1">Numbers of alcohol drinkers (%)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Male</td><td rowspan="1" colspan="1">139 (95.2)</td><td rowspan="1" colspan="1">57 (95.0)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Female</td><td rowspan="1" colspan="1">46 (92.0)</td><td rowspan="1" colspan="1">131 (89.7)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Whole group</td><td rowspan="1" colspan="1">185 (94.4)</td><td rowspan="1" colspan="1">188 (91.3)</td></tr></tbody></table></table-wrap></p><p>Approximately two-thirds of affected individuals were smokers, compared with approximately half of the unaffected LHON carriers (<xref ref-type="table" rid="T1">Tables 1</xref> and <xref ref-type="table" rid="T2">2</xref>). There was no significant difference in mean cumulative tobacco consumption between affected and unaffected LHON carriers (6.57 pack years, SD = 12.37 versus 7.25 pack years, SD = 11.30, <italic>P</italic> = 0.57), but mean maximum intensity of smoking was significantly higher among affected individuals (16.66 cigarettes per day, SD = 19.62 versus 11.55 cigarettes per day, SD = 14.97, <italic>P</italic> &#x0003c; 0.001). <table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Levels of tobacco consumption among LHON carriers and ORs for vision loss</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Affected (%)</th><th rowspan="1" colspan="1">Unaffected (%)</th><th rowspan="1" colspan="1">Mean (SD)</th><th rowspan="1" colspan="1">ORs<xref ref-type="table-fn" rid="TF1"><sup>a</sup></xref> (95% CI)</th><th rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody align="left"><tr><td colspan="6" rowspan="1">Cumulative smoking consumption (Pack years)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;None</td><td rowspan="1" colspan="1">62 (31.6)</td><td rowspan="1" colspan="1">98 (47.6)</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Light smoking</td><td rowspan="1" colspan="1">114 (58.2)</td><td rowspan="1" colspan="1">81 (39.3)</td><td rowspan="1" colspan="1">5.82 (5.45)</td><td rowspan="1" colspan="1">2.23 (1.45&#x02013;3.41)</td><td rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="TF3"><sup>c</sup></xref></td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Heavy smoking</td><td rowspan="1" colspan="1">20 (10.2)</td><td rowspan="1" colspan="1">27 (13.1)</td><td rowspan="1" colspan="1">32.47 (14.63)</td><td rowspan="1" colspan="1">1.17 (0.61&#x02013;2.27)</td><td rowspan="1" colspan="1">0.735</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Whole group<xref ref-type="table-fn" rid="TF2"><sup>b</sup></xref></td><td rowspan="1" colspan="1">134 (68.4)</td><td rowspan="1" colspan="1">108 (52.4)</td><td rowspan="1" colspan="1">11.00 (13.28)</td><td rowspan="1" colspan="1">1.96 (1.31&#x02013;2.95)</td><td rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TF3"><sup>c</sup></xref></td></tr><tr><td colspan="6" rowspan="1">Maximum smoking consumption</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;None</td><td rowspan="1" colspan="1">62 (31.6)</td><td rowspan="1" colspan="1">98 (47.6)</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Light smoking</td><td rowspan="1" colspan="1">78 (39.8)</td><td rowspan="1" colspan="1">80 (38.8)</td><td rowspan="1" colspan="1">12.50 (8.82)</td><td rowspan="1" colspan="1">1.54 (0.99&#x02013;2.41)</td><td rowspan="1" colspan="1">0.071</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Heavy smoking</td><td rowspan="1" colspan="1">56 (28.6)</td><td rowspan="1" colspan="1">28 (13.6)</td><td rowspan="1" colspan="1">42.32 (12.84)</td><td rowspan="1" colspan="1">3.16 (1.82&#x02013;5.50)</td><td rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="TF3"><sup>c</sup></xref></td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Whole group<xref ref-type="table-fn" rid="TF2"><sup>b</sup></xref></td><td rowspan="1" colspan="1">132 (68.4)</td><td rowspan="1" colspan="1">108 (52.4)</td><td rowspan="1" colspan="1">22.85 (17.60)</td><td rowspan="1" colspan="1">1.96 (1.31&#x02013;2.95)</td><td rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TF3"><sup>c</sup></xref></td></tr></tbody></table><table-wrap-foot><fn><p>The light and heavy smoking subgroups were based on whether the subject was below or above the 75th percentile values derived from the level of smoking consumption among unaffected LHON carriers.</p></fn><fn id="TF1"><p>a Comparison to unaffected LHON carriers who were non-smokers.</p></fn><fn id="TF2"><p>b Whole group includes both light and heavy tobacco consumers</p></fn><fn id="TF3"><p>c Significant at <italic>P</italic> &#x0003c; 0.05 level.</p></fn></table-wrap-foot></table-wrap></p><p>The majority of study subjects drank alcohol (94.4% of the affected individuals and 91.2% of the unaffected individuals, <xref ref-type="table" rid="T1">Tables 1</xref> and <xref ref-type="table" rid="T3">3</xref>). Mean cumulative alcohol consumption among affected carriers (41.95 drink years, SD = 68.34) was not significantly different to unaffected carriers (43.26 drink years, SD = 73.39, <italic>P</italic> = 0.853). However, the mean maximum intensity of alcohol consumption for the affected group was significantly higher than for the unaffected group (54.43 U/week, SD = 104.21 versus 23.78 U/week, SD = 36.88, <italic>P</italic> &#x0003c; 0.001). <table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Levels of alcohol consumption among LHON carriers and ORs for vision loss</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Affected (%)</th><th rowspan="1" colspan="1">Unaffected (%)</th><th rowspan="1" colspan="1">Mean (SD)</th><th rowspan="1" colspan="1">OR<xref ref-type="table-fn" rid="TF4"><sup>a</sup></xref> (95% CI)</th><th rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody align="left"><tr><td colspan="6" rowspan="1">Cumulative alcohol consumption (Drink years)</td></tr><tr><td rowspan="1" colspan="1">None</td><td rowspan="1" colspan="1">11 (5.6)</td><td rowspan="1" colspan="1">18 (8.8)</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">Light drinking</td><td rowspan="1" colspan="1">137 (69.9)</td><td rowspan="1" colspan="1">141 (68.4)</td><td rowspan="1" colspan="1">16.10 (16.31)</td><td rowspan="1" colspan="1">1.59 (0.72&#x02013;3.49)</td><td rowspan="1" colspan="1">0.329</td></tr><tr><td rowspan="1" colspan="1">Heavy drinking</td><td rowspan="1" colspan="1">48 (24.5)</td><td rowspan="1" colspan="1">47 (22.8)</td><td rowspan="1" colspan="1">132.02 (99.93)</td><td rowspan="1" colspan="1">1.67 (0.71&#x02013;3.91)</td><td rowspan="1" colspan="1">0.290</td></tr><tr><td rowspan="1" colspan="1">Whole group<xref ref-type="table-fn" rid="TF5"><sup>b</sup></xref></td><td rowspan="1" colspan="1">185 (94.4)</td><td rowspan="1" colspan="1">188 (91.3)</td><td rowspan="1" colspan="1">45.62 (72.66)</td><td rowspan="1" colspan="1">1.61 (0.74&#x02013;3.50)</td><td rowspan="1" colspan="1">0.252</td></tr><tr><td colspan="6" rowspan="1">Maximum alcohol consumption (Units of alcohol per week)</td></tr><tr><td rowspan="1" colspan="1">None</td><td rowspan="1" colspan="1">11 (5.6)</td><td rowspan="1" colspan="1">18 (8.8)</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">Light drinking</td><td rowspan="1" colspan="1">85 (43.4)</td><td rowspan="1" colspan="1">138 (67.0)</td><td rowspan="1" colspan="1">8.32 (8.98)</td><td rowspan="1" colspan="1">1.01 (0.45&#x02013;2.24)</td><td rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">Heavy drinking</td><td rowspan="1" colspan="1">100 (51.0)</td><td rowspan="1" colspan="1">50 (24.3)</td><td rowspan="1" colspan="1">90.95 (110.47)</td><td rowspan="1" colspan="1">3.27 (1.44&#x02013;7.46)</td><td rowspan="1" colspan="1">0.006<xref ref-type="table-fn" rid="TF6"><sup>c</sup></xref></td></tr><tr><td rowspan="1" colspan="1">Whole group<xref ref-type="table-fn" rid="TF5"><sup>b</sup></xref></td><td rowspan="1" colspan="1">185 (94.4)</td><td rowspan="1" colspan="1">188 (91.3)</td><td rowspan="1" colspan="1">41.55 (81.13)</td><td rowspan="1" colspan="1">1.61 (0.74&#x02013;3.50)</td><td rowspan="1" colspan="1">0.252</td></tr></tbody></table><table-wrap-foot><fn><p>The light and heavy smoking subgroups were based on whether the subject was below or above the 75th percentile values derived from the level of alcohol consumption among unaffected LHON carriers.</p></fn><fn id="TF4"><p>a Comparison to unaffected LHON carriers who were non-drinkers.</p></fn><fn id="TF5"><p>b Whole group includes both light and heavy alcohol consumers</p></fn><fn id="TF6"><p>c Significant at <italic>P</italic> &#x0003c; 0.05 level.</p></fn></table-wrap-foot></table-wrap></p><p>Kaplan&#x02013;Meier survival analysis revealed significant relationships with (i) cumulative smoking, (ii) maximum intensity smoking and (iii) maximum intensity drinking, but not cumulative drinking (<xref ref-type="fig" rid="F3 F4">Figs 3 and 4</xref>). These initial results suggested that both smoking and alcohol consumption increased the risk of visual failure in LHON pedigrees. However, male carriers drank and smoked more than female carriers (maximum smoking: <italic>P</italic> = 0.001; cumulative smoking <italic>P</italic> = 0.096; maximum alcohol: <italic>P</italic> &#x0003c; 0.001; cumulative alcohol: <italic>P</italic> &#x0003c; 0.001), raising the possibility that the apparent association of visual loss with alcohol and smoking could actually be secondary to the gender bias in LHON i.e. the greater number of affected males. To address this issue, binary logistic regression was performed which allows a more stringent statistical analysis by simultaneously analysing all the variables that could influence the risk of a LHON carrier converting, therefore minimizing the chance of detecting a spurious statistical association. <fig id="F3" position="float"><label>Figure 3</label><caption><p>Kaplan&#x02013;Meier curve showing the disease onset according to tobacco consumption. (<bold>A</bold>) Cumulative smoking (<italic>P</italic> &#x0003c; 0.001 by log-rank test). (<bold>B</bold>) Maximum intensity smoking (<italic>P</italic> = 0.011 by log-rank test).</p></caption><graphic xlink:href="awp158f3"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><p>Kaplan&#x02013;Meier curve showing the disease onset according to alcohol consumption. (<bold>A</bold>) Cumulative drinking (<italic>P</italic> = 0.108 by log-rank test). (<bold>B</bold>) Maximum intensity drinking (<italic>P</italic> &#x0003c; 0.001 by log-rank test).</p></caption><graphic xlink:href="awp158f4"/></fig></p><p>With smoking and alcohol consumption treated as categorical variables in the logistic regression model, both light (OR = 1.93; 95% CI = 1.08&#x02013;3.46; <italic>P</italic> = 0.027) and heavy (OR = 3.26; 95% CI = 1.31&#x02013;8.07; <italic>P</italic> = 0.011) cumulative smoking were independent risk factors for visual failure compared with the non-smoking group, but for maximum smoking intensity, only heavy smoking (OR = 2.80; 95% CI = 1.31&#x02013;5.99; <italic>P</italic> = 0.008) showed a significant association (<xref ref-type="table" rid="T4">Table 4</xref>). When analysed as continuous variables, both cumulative (OR = 1.04; 95% CI = 1.01&#x02013;1.06; <italic>P</italic> = 0.004) and maximum intensity (OR = 1.02; 95% CI = 1.00&#x02013;1.04; <italic>P</italic> = 0.021) of smoking were significantly associated with increased risk of visual loss (<xref ref-type="table" rid="T5">Table 5</xref>). Although there was a trend towards a greater likelihood of conversion among LHON carriers who were heavy drinkers (&#x02265;75th percentile), both cumulative and maximum intensity of alcohol consumption did not reach statistical significance either as categorical or continuous variables (<xref ref-type="table" rid="T4">Tables 4</xref> and <xref ref-type="table" rid="T5">5</xref>). There was also no significant statistical interaction between smoking, alcohol and gender intake when considered as either continuous or categorical variables. Further evidence that gender and smoking are independent risk factors for visual failure in LHON was apparent from Kaplan&#x02013;Meier survival analysis of male and female smokers and non-smokers. Clinical penetrance was greater in male non-smokers than female non-smokers (<xref ref-type="fig" rid="F5">Fig. 5</xref>A, <italic>P</italic> &#x0003c; 0.001). However, the striking effect of smoking in males was associated with a 93% life-time penetrance of visual failure, compared with only 66% in non-smoking males and 33% in smoking females (<xref ref-type="fig" rid="F5">Fig. 5</xref>B, <italic>P</italic> &#x0003c; 0.001). <fig id="F5" position="float"><label>Figure 5</label><caption><p>Kaplan&#x02013;Meier curve showing the disease onset according to gender and smoking status. (<bold>A</bold>) Non-smoking individuals (<italic>P</italic> &#x0003c; 0.001 by log-rank test). (<bold>B</bold>) Smoking individuals (<italic>P</italic> &#x0003c; 0.001 by log-rank test).</p></caption><graphic xlink:href="awp158f5"/></fig><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Binary logistic regression models for the prediction of vision loss: categorical consumption levels of tobacco and alcohol</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1"/><th colspan="2" rowspan="1">Model 1 (cumulative)<hr/></th><th colspan="2" rowspan="1">Model 2 (maximum)<hr/></th></tr><tr><th rowspan="1" colspan="1">Predictor variables</th><th rowspan="1" colspan="1">ORs (95% CI)</th><th rowspan="1" colspan="1"><italic>P</italic>-value</th><th rowspan="1" colspan="1">ORs (95% CI)</th><th rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1">Light smoking<xref ref-type="table-fn" rid="TF7"><sup>a</sup></xref></td><td rowspan="1" colspan="1">1.93 (1.08&#x02013;3.46)</td><td rowspan="1" colspan="1">0.027<xref ref-type="table-fn" rid="TF9"><sup>c</sup></xref></td><td rowspan="1" colspan="1">1.63 (0.88&#x02013;3.02)</td><td rowspan="1" colspan="1">0.118</td></tr><tr><td rowspan="1" colspan="1">Heavy smoking<xref ref-type="table-fn" rid="TF7"><sup>a</sup></xref></td><td rowspan="1" colspan="1">3.26 (1.31&#x02013;8.07)</td><td rowspan="1" colspan="1">0.011<xref ref-type="table-fn" rid="TF9"><sup>c</sup></xref></td><td rowspan="1" colspan="1">2.80 (1.31&#x02013;5.99)</td><td rowspan="1" colspan="1">0.008<xref ref-type="table-fn" rid="TF9"><sup>c</sup></xref></td></tr><tr><td rowspan="1" colspan="1">Light drinking<xref ref-type="table-fn" rid="TF8"><sup>b</sup></xref></td><td rowspan="1" colspan="1">1.52 (0.50&#x02013;4.64)</td><td rowspan="1" colspan="1">0.459</td><td rowspan="1" colspan="1">1.32 (0.44&#x02013;3.98)</td><td rowspan="1" colspan="1">0.625</td></tr><tr><td rowspan="1" colspan="1">Heavy drinking<xref ref-type="table-fn" rid="TF8"><sup>b</sup></xref></td><td rowspan="1" colspan="1">2.75 (0.76&#x02013;10.02)</td><td rowspan="1" colspan="1">0.125</td><td rowspan="1" colspan="1">2.31 (0.73&#x02013;7.30)</td><td rowspan="1" colspan="1">0.154</td></tr></tbody></table><table-wrap-foot><fn id="TF7"><p>a Comparison with non-smokers.</p></fn><fn id="TF8"><p>b Comparison with non-drinkers</p></fn><fn id="TF9"><p>c Significant at <italic>P</italic> &#x0003c; 0.05 level. Both models also incorporated the following variables: age, gender and LHON mutation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T5" position="float"><label>Table 5</label><caption><p>Binary logistic regression models for the prediction of vision loss: continuous consumption levels of tobacco and alcohol</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1"/><th colspan="2" rowspan="1">Model 3 (cumulative)<hr/></th><th colspan="2" rowspan="1">Model 4 (maximum)<hr/></th></tr><tr><th rowspan="1" colspan="1">Predictor variables</th><th rowspan="1" colspan="1">ORs (95% CI)</th><th rowspan="1" colspan="1"><italic>P</italic>-value</th><th rowspan="1" colspan="1">ORs (95% CI)</th><th rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1">Smoking</td><td rowspan="1" colspan="1">1.04 (1.01&#x02013;1.06)</td><td rowspan="1" colspan="1">0.004<xref ref-type="table-fn" rid="TF10"><sup>a</sup></xref></td><td rowspan="1" colspan="1">1.02 (1.00&#x02013;1.04)</td><td rowspan="1" colspan="1">0.021<xref ref-type="table-fn" rid="TF10"><sup>a</sup></xref></td></tr><tr><td rowspan="1" colspan="1">Alcohol</td><td rowspan="1" colspan="1">1.00 (1.00&#x02013;1.01)</td><td rowspan="1" colspan="1">0.093</td><td rowspan="1" colspan="1">1.00 (1.00&#x02013;1.01)</td><td rowspan="1" colspan="1">0.176</td></tr></tbody></table><table-wrap-foot><fn id="TF10"><p>a Significant at <italic>P</italic> &#x0003c; 0.05 level. Both models also incorporated the following variables: age, gender and LHON mutation.</p></fn></table-wrap-foot></table-wrap></p><p>The most commonly reported triggers for visual loss were psychological stress (13.3%, <italic>n</italic> = 26) and physical trauma (5.6%, <italic>n</italic> = 11), with other subjects reporting a concurrent physical illness (4.6%, <italic>n</italic> = 9), poor nutrition (0.5%, <italic>n</italic> = 1) and chemotherapy (0.5%, <italic>n</italic> = 1) as significant personal events prior to the onset of symptoms. The nature of the physical trauma included head injury (<italic>n</italic> = 7), road traffic accident (<italic>n</italic> = 3) and limb injury (<italic>n</italic> = 1). A proportion of affected LHON carriers (33.7%, <italic>n</italic> = 66) also reported occupational or accidental toxin exposure in the immediate period preceding visual loss, which included exhaust fumes (<italic>n</italic> = 16), dry cleaning solvents (<italic>n</italic> = 13), asbestos (<italic>n</italic> = 5), lead (<italic>n</italic> = 4), scrap metals (<italic>n</italic> = 4) and fibreglass (<italic>n</italic> = 2), at high levels not encountered in a normal environment. There was no significant difference between affected and unaffected LHON carriers in their diet, level of physical exercise, recreational drugs, medication history or medical comorbidity.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>The evidence supporting the role of environmental risk factors in precipitating the optic neuropathy in LHON has so far been largely based on anecdotal reports (DuBios and Feldon, <xref ref-type="bibr" rid="B7">1992</xref>; Golnik and Shaible, <xref ref-type="bibr" rid="B9">1994</xref>; Rizzo, <xref ref-type="bibr" rid="B28">1995</xref>; Hwang and Park, <xref ref-type="bibr" rid="B14">1996</xref>; Mackey <italic>et al</italic>., <xref ref-type="bibr" rid="B18">2003</xref>; Sanchez <italic>et al</italic>., <xref ref-type="bibr" rid="B30">2006</xref>; Carelli <italic>et al</italic>., <xref ref-type="bibr" rid="B4">2007</xref>) and small case series (Newman <italic>et al</italic>., <xref ref-type="bibr" rid="B23">1991</xref>; Cullom <italic>et al</italic>., <xref ref-type="bibr" rid="B6">1993</xref>; Riordan-Eva <italic>et al</italic>., <xref ref-type="bibr" rid="B27">1995</xref>). Larger studies specifically investigating the role of tobacco and alcohol have produced conflicting results (Chalmers and Harding, <xref ref-type="bibr" rid="B5">1996</xref>; Tsao <italic>et al</italic>., <xref ref-type="bibr" rid="B37">1999</xref>; Kerrison <italic>et al</italic>., <xref ref-type="bibr" rid="B16">2000</xref>; Sadun <italic>et al</italic>., <xref ref-type="bibr" rid="B29">2003</xref>) (<xref ref-type="table" rid="T6">Table 6</xref>). Two separate studies of large m.11778G&#x0003e;A LHON pedigrees did suggest an important role for smoking in disease conversion (Tsao <italic>et al</italic>., <xref ref-type="bibr" rid="B37">1999</xref>; Sadun <italic>et al</italic>., <xref ref-type="bibr" rid="B29">2003</xref>), but crucially, only one study (Kerrison <italic>et al</italic>., <xref ref-type="bibr" rid="B16">2000</xref>) considered exposure levels before the onset of visual loss. By carrying out the largest study to date, and controlling for the major factors known to influence disease penetrance, we have provided strong evidence that smoking is associated with an increased risk of visual failure among LHON carriers. For both cumulative and maximum intensity levels, heavy smokers were also more likely to be affected than light smokers, providing further support for a biologically plausible dose&#x02013;response relationship. <table-wrap id="T6" position="float"><label>Table 6</label><caption><p>Summary of previous studies assessing the role of smoking and alcohol in LHON</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1">References</th><th rowspan="1" colspan="1">Study group</th><th rowspan="1" colspan="1">Main findings</th><th rowspan="1" colspan="1">Limitations</th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1">Chalmers and Harding, <xref ref-type="bibr" rid="B5">1996</xref></td><td rowspan="1" colspan="1">50 unrelated, matched controls.</td><td rowspan="1" colspan="1">Maximum alcohol and tobacco consumption were analysed at the time of onset of visual symptoms.</td><td rowspan="1" colspan="1">Small sample size.</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">50 affected LHON carriers with one of the three primary LHON mutations: m.11778G&#x0003e;A, <italic>n</italic> = 35 m.3460G&#x0003e;A, <italic>n</italic> = 8 m.14484T&#x0003e;C, <italic>n</italic> = 7.</td><td rowspan="1" colspan="1">Alcohol, but not tobacco consumption, was significantly higher among affected patients compared with controls.</td><td rowspan="1" colspan="1">Cumulative consumption and variation over the years preceding visual loss was not recorded.</td></tr><tr><td rowspan="1" colspan="1">Tsao <italic>et al</italic>., <xref ref-type="bibr" rid="B37">1999</xref></td><td rowspan="1" colspan="1">A North American pedigree of 65 family members harbouring the m.11778G&#x0003e;A mutation</td><td rowspan="1" colspan="1">Tobacco consumption was compared between affected and unaffected family members at the two age cut-offs of 25 and 35 years.</td><td rowspan="1" colspan="1">Small sample size.</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">All affected carriers were smokers compared with only 25&#x02013;42% of unaffected carriers.</td><td rowspan="1" colspan="1">Cumulative consumption and variation over the years preceding visual loss was not recorded.</td></tr><tr><td rowspan="1" colspan="1">Kerrison <italic>et al</italic>., <xref ref-type="bibr" rid="B16">2000</xref></td><td rowspan="1" colspan="1">103 affected and 158 unaffected from 80 LHON pedigrees: m.11778G&#x0003e;A, <italic>n</italic> = 63 m.3460G&#x0003e;A, <italic>n</italic> = 7 m.14484T&#x0003e;C, <italic>n</italic> = 10</td><td rowspan="1" colspan="1">Maximum intensity and cumulative consumption of tobacco or alcohol were not associated with an increased risk of visual loss.</td><td rowspan="1" colspan="1">Possibility of ascertainment bias since only 56% of postal questionnaires were returned</td></tr><tr><td rowspan="1" colspan="1">Sadun <italic>et al</italic>., <xref ref-type="bibr" rid="B29">2003</xref></td><td rowspan="1" colspan="1">A large Brazilian pedigree of 265 family members harbouring the m.11778G&#x0003e;A mutation.</td><td rowspan="1" colspan="1">Disease penetrance was significantly higher among smokers but not drinkers.</td><td rowspan="1" colspan="1">Actual consumption levels were not quantified, only whether an individual drank or smoked.</td></tr></tbody></table></table-wrap></p><p>Our LHON cohort is comparable with other published epidemiological case series, with a predominance of the m.11778G&#x0003e;A mutation, most patients becoming affected in their twenties, and males having a higher risk of visual loss than female carriers. The gender bias was slightly lower than the figures reported in previous LHON case series, where males were on average five times more likely to be affected than female carriers (Man <italic>et al</italic>., <xref ref-type="bibr" rid="B21">2002</xref>; Yu-Wai-Man, <xref ref-type="bibr" rid="B39">2009</xref>). Although this discrepancy can be accounted for by the recruitment of a proportionally larger number of affected female carriers, this ascertainment bias is unlikely to affect the general applicability of our findings.</p><p>Initial analysis of our dataset indicated an increased risk of disease conversion among LHON carriers who were heavy drinkers. However, after controlling for possible confounding variables such as age, gender and the primary LHON mutations using a logistic regression model, both cumulative and maximum intensity of alcohol failed to reach statistical significance. The trend towards a significant relationship between visual loss and heavy alcohol intake suggests a weaker causal relationship between levels of alcohol consumption and visual failure, but this cannot be substantiated at present. Although we aimed to investigate the role of other environmental triggers in LHON, besides smoking and alcohol, and about a third of our patients reported possible insults prior to the onset of visual loss, the retrospective nature of our study made it difficult to draw any firm conclusions regarding their actual relevance.</p><p>What pathophysiological mechanisms could explain the increased susceptibility to optic neuropathy among smoking LHON carriers? Oxidative phosphorylation (OXPHOS) produces most of the adenosine triphosphate (ATP) requirements and this process is achieved by a chain of five respiratory complexes (I&#x02013;V) along the inner mitochondrial membrane. All three primary LHON mutations result in amino acid substitutions within subunits that assemble into Complex I and depending on the experimental assays used, a mild to moderate reduction in respiratory chain activity has been identified (Yu-Wai-Man <italic>et al</italic>., <xref ref-type="bibr" rid="B39">2009</xref>). Cigarette smoking could potentiate this energy deficit by either compromising complex I activity directly (Smith <italic>et al</italic>., <xref ref-type="bibr" rid="B33">1993</xref>, <xref ref-type="bibr" rid="B34">1994</xref>), or limiting OXPHOS through elevated carboxyhaemoglobin levels and a reduction in arterial oxygen content (Gvozdjak <italic>et al</italic>., <xref ref-type="bibr" rid="B10">1987</xref>; van Jaarsveld <italic>et al</italic>., <xref ref-type="bibr" rid="B38">1992</xref>). In a study, cytochrome <italic>c</italic> oxidase (COX, complex IV) activity in rats was reduced by 25% after 30 min exposure to cigarette smoke, and prolonged exposure resulted in further decreases in COX activity (Gvozdjak <italic>et al</italic>., <xref ref-type="bibr" rid="B10">1987</xref>). This led to an increase in reactive oxygen species, which have been implicated as potent triggers of apoptosis and retinal ganglion cell loss in LHON (Yu-Wai-Man <italic>et al</italic>., <xref ref-type="bibr" rid="B39">2009</xref>). There is also a suggestion that secondary mtDNA abnormalities are more prevalent among smokers, with an increased rate of somatic mtDNA mutations and a compensatory increase in mtDNA copy number (Tan <italic>et al</italic>., <xref ref-type="bibr" rid="B36">2008</xref>). These findings are consistent with a deleterious effect of smoking on mitochondrial biogenesis, which potentially could further exacerbate the pre-existing LHON-induced complex I defect in retinal ganglion cells, precipitating the onset of optic nerve dysfunction.</p><p>We identified 15 individuals who reported visual loss before the age of 10 years, none of whom had consumed tobacco or alcohol prior to visual loss, and there was not an increased rate of smoking among close family members compared with the rest of the affected group. This is in keeping with the prevailing view that LHON is a multifactorial disease, and the visual failure is likely due to a complex interaction between genetic and environmental factors, with smoking as only one of the susceptibility factors. Although we applied a stringent logistic regression model to reduce the risk of finding a spurious association, the nature of our study did not allow us to control for the influence of mtDNA haplogroups (Hudson <italic>et al</italic>., <xref ref-type="bibr" rid="B12">2007</xref>) and the presence or absence of the high-risk haplotype at Xp21 which has been shown to increase the risk of visual failure &#x0223c;35-fold for the m.11778G&#x0003e;A and m.14484T&#x0003e;C mutations but not for m.3460G&#x0003e;A (Hudson <italic>et al</italic>., <xref ref-type="bibr" rid="B13">2005</xref>). However, our results clearly indicate that future association studies of possible nuclear modifier genes in LHON should ideally control for the level of smoking and alcohol consumption in any analyses performed. Being a retrospective study based upon telephone interviews, our study was also potentially subject to recall bias, with patients reporting information about their alcohol and smoking history over a time period sometimes spanning several decades.</p><p>Our large multi-centre study of 125 LHON pedigrees has revealed an important and consistent role for smoking in increasing disease penetrance among carriers of the three primary mtDNA mutations. Perhaps the most striking finding is that 93% of men who smoke develop visual failure if they harbour the LHON mtDNA mutation. The effect of smoking is also apparent in women, albeit with a reduced overall clinical penetrance due to the gender bias. These findings have important practical implications for genetic counselling and LHON carriers should be strongly advised not to smoke. Although the association between visual failure and heavy alcohol consumption was not statistically significant in the logistic regression analysis, it would also seem sensible for LHON mutation carriers to moderate their alcohol intake and avoid binge drinking episodes.</p></sec><sec sec-type="supplementary-material"><title>Supplementary material</title><p><ext-link ext-link-type="uri" xlink:href="http://brain.oxfordjournals.org/cgi/content/full/awp158/DC1">Supplementary material</ext-link> is available at <italic>Brain</italic> online.</p></sec><sec><title>Funding</title><p>Funding to pay the Open Access publication charges for this article was provided by The Wellcome Trust.</p></sec></body><back><ack><title>Acknowledgements</title><p>PFC is a Wellcome Trust Senior Fellow in Clinical Science who also receives funding from the Medical Research Council (UK), the UK Parkinson's Disease Society and the UK NIHR Biomedical Research Centre for Ageing and Age-related disease award to the Newcastle upon Tyne Foundation Hospitals NHS Trust. PYWM is an MRC Research Fellow. This research was presented at the 2009 American Academy of Neurology Annual Meeting with support from a Brain Travel Grant to MAK. We would like to thank the Dutch patients&#x02019; association &#x02018;De LOA-contactgroep&#x02019; (Eindhoven) for their contribution and all the LHON families who have kindly taken part in this survey.</p></ack><ref-list><title>References</title><ref id="B1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biousse</surname><given-names>V</given-names></name><name><surname>Browne</surname><given-names>MD</given-names></name><name><surname>Newman</surname><given-names>NJ</given-names></name><name><surname>Allen</surname><given-names>JC</given-names></name><name><surname>Rosenfeld</surname><given-names>J</given-names></name><name><surname>Meola</surname><given-names>G</given-names></name><etal/></person-group><article-title>De novo 14484 mitochondrial DNA mutation in monozygotic twins discordant for Leber's hereditary optic neuropathy</article-title><source>Neurology</source><year>1997</year><volume>49</volume><fpage>1136</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9339703</pub-id></element-citation></ref><ref id="B2"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bland</surname><given-names>M</given-names></name></person-group><source>An Introduction to medical statistics</source><year>2000</year><edition>3rd</edition><publisher-loc>Oxford</publisher-loc><publisher-name>Oxford University Press</publisher-name></element-citation></ref><ref id="B3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>MD</given-names></name><name><surname>Wallace</surname><given-names>DC</given-names></name></person-group><article-title>Spectrum of mitochondrial-DNA mutations in Lebers hereditary optic neuropathy</article-title><source>Clin Neurosci</source><year>1994</year><volume>2</volume><fpage>138</fpage><lpage>45</lpage></element-citation></ref><ref id="B4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carelli</surname><given-names>V</given-names></name><name><surname>Franceschini</surname><given-names>F</given-names></name><name><surname>Venturi</surname><given-names>S</given-names></name><name><surname>Barboni</surname><given-names>P</given-names></name><name><surname>Savini</surname><given-names>G</given-names></name><name><surname>Barbieri</surname><given-names>G</given-names></name><etal/></person-group><article-title>Grand rounds: Could occupational exposure to n-hexane and other solvents precipitate visual failure in Leber hereditary optic neuropathy?</article-title><source>Environ Health Perspect</source><year>2007</year><volume>115</volume><fpage>113</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">17366829</pub-id></element-citation></ref><ref id="B5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalmers</surname><given-names>RM</given-names></name><name><surname>Harding</surname><given-names>AE</given-names></name></person-group><article-title>A case-control study of Leber's hereditary optic neuropathy</article-title><source>Brain</source><year>1996</year><volume>119</volume><fpage>1481</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8931573</pub-id></element-citation></ref><ref id="B6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cullom</surname><given-names>ME</given-names></name><name><surname>Heher</surname><given-names>KL</given-names></name><name><surname>Miller</surname><given-names>NR</given-names></name><name><surname>Savino</surname><given-names>PJ</given-names></name><name><surname>Johns</surname><given-names>DR</given-names></name></person-group><article-title>Leber's hereditary optic neuropathy masquerading as tobacco-alcohol amblyopia</article-title><source>Arch Ophthalmol</source><year>1993</year><volume>111</volume><fpage>1482</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">8240101</pub-id></element-citation></ref><ref id="B7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DuBois</surname><given-names>LG</given-names></name><name><surname>Feldon</surname><given-names>SE</given-names></name></person-group><article-title>Evidence for a metabolic trigger for Leber's hereditary optic neuropathy. A case report</article-title><source>J Clin Neuro-Ophthalmol</source><year>1992</year><volume>12</volume><fpage>15</fpage><lpage>16</lpage></element-citation></ref><ref id="B8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>HR</given-names></name><name><surname>Samuels</surname><given-names>DC</given-names></name><name><surname>Eden</surname><given-names>JA</given-names></name><name><surname>Relton</surname><given-names>CL</given-names></name><name><surname>Chinnery</surname><given-names>PF</given-names></name></person-group><article-title>Pathogenic mitochondrial DNA mutations are common in the general population</article-title><source>Am J Hum Genet</source><year>2008</year><volume>83</volume><fpage>254</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">18674747</pub-id></element-citation></ref><ref id="B9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golnik</surname><given-names>KC</given-names></name><name><surname>Schaible</surname><given-names>ER</given-names></name></person-group><article-title>Folate-responsive optic neuropathy</article-title><source>J Neuroophthalmol</source><year>1994</year><volume>14</volume><fpage>163</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7804421</pub-id></element-citation></ref><ref id="B10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gvozdjak</surname><given-names>J</given-names></name><name><surname>Gvozdjakova</surname><given-names>A</given-names></name><name><surname>Kucharska</surname><given-names>J</given-names></name><name><surname>Bada</surname><given-names>V</given-names></name></person-group><article-title>The effect of smoking on myocardial metabolism</article-title><source>Czech Med</source><year>1987</year><volume>10</volume><fpage>47</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">3034529</pub-id></element-citation></ref><ref id="B11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname><given-names>AE</given-names></name><name><surname>Sweeney</surname><given-names>MG</given-names></name><name><surname>Govan</surname><given-names>GG</given-names></name><name><surname>Riordan-Eva</surname><given-names>P</given-names></name></person-group><article-title>Pedigree analysis in Leber hereditary optic neuropathy families with a pathogenic mtDNA mutation</article-title><source>Am J Hum Genet</source><year>1995</year><volume>57</volume><fpage>77</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">7611298</pub-id></element-citation></ref><ref id="B12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hudson</surname><given-names>G</given-names></name><name><surname>Carelli</surname><given-names>V</given-names></name><name><surname>Spruijt</surname><given-names>L</given-names></name><name><surname>Gerards</surname><given-names>M</given-names></name><name><surname>Mowbray</surname><given-names>C</given-names></name><name><surname>Achilli</surname><given-names>A</given-names></name><etal/></person-group><article-title>Clinical expression of Leber hereditary optic neuropathy is affected by the mitochondrial DNA-haplogroup background</article-title><source>Am J Hum Genet</source><year>2007</year><volume>81</volume><fpage>228</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">17668373</pub-id></element-citation></ref><ref id="B13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hudson</surname><given-names>G</given-names></name><name><surname>Keers</surname><given-names>S</given-names></name><name><surname>Yu-Wai-Man</surname><given-names>P</given-names></name><name><surname>Griffiths</surname><given-names>P</given-names></name><name><surname>Huponen</surname><given-names>K</given-names></name><name><surname>Savontaus</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Identification of an X-chromosomal locus and haplotype modulating the phenotype of a mitochondrial DNA disorder</article-title><source>Am J Hum Genet</source><year>2005</year><volume>77</volume><fpage>1086</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">16380918</pub-id></element-citation></ref><ref id="B14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>JM</given-names></name><name><surname>Park</surname><given-names>HW</given-names></name></person-group><article-title>Carbon monoxide poisoning as an epigenetic factor for Leber's hereditary optic neuropathy</article-title><source>Korean J Ophthalmol</source><year>1996</year><volume>10</volume><fpage>122</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">9055542</pub-id></element-citation></ref><ref id="B15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johns</surname><given-names>DR</given-names></name><name><surname>Smith</surname><given-names>KH</given-names></name><name><surname>Miller</surname><given-names>NR</given-names></name><name><surname>Sulewski</surname><given-names>ME</given-names></name><name><surname>Bias</surname><given-names>WB</given-names></name></person-group><article-title>Identical twins who are discordant for Leber's hereditary optic neuropathy</article-title><source>Arch Ophthalmol</source><year>1993</year><volume>111</volume><fpage>1491</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">8240103</pub-id></element-citation></ref><ref id="B16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerrison</surname><given-names>JB</given-names></name><name><surname>Miller</surname><given-names>NR</given-names></name><name><surname>Hsu</surname><given-names>F</given-names></name><name><surname>Beaty</surname><given-names>TH</given-names></name><name><surname>Maumenee</surname><given-names>IH</given-names></name><name><surname>Smith</surname><given-names>KH</given-names></name><etal/></person-group><article-title>A case-control study of tobacco and alcohol consumption in Leber's hereditary optic neuropathy</article-title><source>Am J Ophthalmol</source><year>2000</year><volume>130</volume><fpage>803</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">11124301</pub-id></element-citation></ref><ref id="B17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>BL</given-names></name></person-group><article-title>Identical twins no longer discordant for Leber's hereditary optic neuropathy</article-title><source>Arch Ophthalmol</source><year>1998</year><volume>116</volume><fpage>956</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9682718</pub-id></element-citation></ref><ref id="B18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackey</surname><given-names>DA</given-names></name><name><surname>Fingert</surname><given-names>JH</given-names></name><name><surname>Luzhansky</surname><given-names>JZ</given-names></name><name><surname>McCluckey</surname><given-names>PJ</given-names></name><name><surname>Howell</surname><given-names>N</given-names></name><name><surname>Hall</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Leber's hereditary optic neuropathy triggered by antiretroviral therapy for human immunodeficiency virus</article-title><source>Eye</source><year>2003</year><volume>17</volume><fpage>312</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12724691</pub-id></element-citation></ref><ref id="B19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackey</surname><given-names>DA</given-names></name><name><surname>Oostra</surname><given-names>RJ</given-names></name><name><surname>Rosenberg</surname><given-names>T</given-names></name><name><surname>Nikoskelainen</surname><given-names>E</given-names></name><name><surname>Bronte-Stewart</surname><given-names>J</given-names></name><name><surname>Poulton</surname><given-names>J</given-names></name><etal/></person-group><article-title>Primary pathogenic mtDNA mutations in multigeneration pedigrees with Leber hereditary optic neuropathy</article-title><source>Am J Hum Genet</source><year>1996</year><volume>59</volume><fpage>481</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">8755941</pub-id></element-citation></ref><ref id="B20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Man</surname><given-names>PY</given-names></name><name><surname>Griffiths</surname><given-names>PG</given-names></name><name><surname>Brown</surname><given-names>DT</given-names></name><name><surname>Howell</surname><given-names>N</given-names></name><name><surname>Turnbull</surname><given-names>DM</given-names></name><name><surname>Chinnery</surname><given-names>PF</given-names></name></person-group><article-title>The epidemiology of Leber hereditary optic neuropathy in the North East of England</article-title><source>Am J Hum Genet</source><year>2003</year><volume>72</volume><fpage>333</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12518276</pub-id></element-citation></ref><ref id="B21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Man</surname><given-names>PY</given-names></name><name><surname>Turnbull</surname><given-names>DM</given-names></name><name><surname>Chinnery</surname><given-names>PF</given-names></name></person-group><article-title>Leber hereditary optic neuropathy</article-title><source>J Med Genet</source><year>2002</year><volume>39</volume><fpage>162</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11897814</pub-id></element-citation></ref><ref id="B22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>NJ</given-names></name><name><surname>Biousse</surname><given-names>V</given-names></name></person-group><article-title>Hereditary optic neuropathies</article-title><source>Eye</source><year>2004</year><volume>18</volume><fpage>1144</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">15534600</pub-id></element-citation></ref><ref id="B23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>NJ</given-names></name><name><surname>Lott</surname><given-names>MT</given-names></name><name><surname>Wallace</surname><given-names>DC</given-names></name></person-group><article-title>The clinical characteristics of pedigrees of Leber's hereditary optic neuropathy with the 11778 mutation</article-title><source>Am J Ophthalmol</source><year>1991</year><volume>111</volume><fpage>750</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">2039048</pub-id></element-citation></ref><ref id="B24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikoskelainen</surname><given-names>EK</given-names></name></person-group><article-title>Clinical picture of LHON</article-title><source>Clin Neurosci</source><year>1994</year><volume>2</volume><fpage>115</fpage><lpage>20</lpage></element-citation></ref><ref id="B25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikoskelainen</surname><given-names>EK</given-names></name><name><surname>Savontaus</surname><given-names>ML</given-names></name><name><surname>Wanne</surname><given-names>OP</given-names></name><name><surname>Katila</surname><given-names>MJ</given-names></name><name><surname>Nummelin</surname><given-names>KU</given-names></name></person-group><article-title>Leber's hereditary optic neuropathy a maternally inherited disease. A genealogic study in four pedigrees</article-title><source>Arch Ophthalmol</source><year>1987</year><volume>105</volume><fpage>665</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">3619743</pub-id></element-citation></ref><ref id="B26"><element-citation publication-type="book"><collab>Office for National Statistics</collab><source>National Statistics Methodological Series No. 37: estimating alcohol consumption from survey data: updated method of converting volumes to units</source><year>2007</year><publisher-loc>Newport, Wales</publisher-loc><publisher-name>Office for National Statistics</publisher-name></element-citation></ref><ref id="B27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riordan-Eva</surname><given-names>P</given-names></name><name><surname>Sanders</surname><given-names>MD</given-names></name><name><surname>Govan</surname><given-names>GG</given-names></name><name><surname>Sweeney</surname><given-names>MG</given-names></name><name><surname>Da Costa</surname><given-names>J</given-names></name><name><surname>Harding</surname><given-names>AE</given-names></name></person-group><article-title>Clinical features of Leber's hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation</article-title><source>Brain</source><year>1995</year><volume>118</volume><fpage>319</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">7735876</pub-id></element-citation></ref><ref id="B28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizzo</surname><given-names>JF</given-names><suffix>III</suffix></name></person-group><article-title>Adenosine triphosphate deficiency: a genre of optic neuropathy</article-title><source>Neurology</source><year>1995</year><volume>45</volume><fpage>11</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">7824099</pub-id></element-citation></ref><ref id="B29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadun</surname><given-names>AA</given-names></name><name><surname>Carelli</surname><given-names>V</given-names></name><name><surname>Salomao</surname><given-names>SR</given-names></name><name><surname>Berezovsky</surname><given-names>A</given-names></name><name><surname>Quiros</surname><given-names>PA</given-names></name><name><surname>Sadun</surname><given-names>F</given-names></name><etal/></person-group><article-title>Extensive investigation of a large Brazilian pedigree of 11778/haplogroup J Leber hereditary optic neuropathy</article-title><source>Am J Ophthalmol</source><year>2003</year><volume>136</volume><fpage>231</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12888043</pub-id></element-citation></ref><ref id="B30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>RN</given-names></name><name><surname>Smith</surname><given-names>AJ</given-names></name><name><surname>Carelli</surname><given-names>V</given-names></name><name><surname>Sadun</surname><given-names>AA</given-names></name><name><surname>Keltner</surname><given-names>JL</given-names></name></person-group><article-title>Leber hereditary optic neuropathy possibly triggered by exposure to tire fire</article-title><source>J Neuroophthalmol</source><year>2006</year><volume>26</volume><fpage>268</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">17204920</pub-id></element-citation></ref><ref id="B31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seedorff</surname><given-names>T</given-names></name></person-group><article-title>The inheritance of Leber's disease. A genealogical follow-up study</article-title><source>Acta Ophthalmol</source><year>1985</year><volume>63</volume><fpage>135</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">4003041</pub-id></element-citation></ref><ref id="B32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shankar</surname><given-names>SP</given-names></name><name><surname>Fingert</surname><given-names>JH</given-names></name><name><surname>Carelli</surname><given-names>V</given-names></name><name><surname>Valentino</surname><given-names>ML</given-names></name><name><surname>King</surname><given-names>TM</given-names></name><name><surname>Daiger</surname><given-names>SP</given-names></name><etal/></person-group><article-title>Evidence for a novel x-linked modifier locus for leber hereditary optic neuropathy</article-title><source>Ophthalmic Genet</source><year>2008</year><volume>29</volume><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">18363168</pub-id></element-citation></ref><ref id="B33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>PR</given-names></name><name><surname>Cooper</surname><given-names>JM</given-names></name><name><surname>Govan</surname><given-names>GG</given-names></name><name><surname>Harding</surname><given-names>AE</given-names></name><name><surname>Schapira</surname><given-names>AH</given-names></name></person-group><article-title>Smoking and mitochondrial function: a model for environmental toxins</article-title><source>Q J Med</source><year>1993</year><volume>86</volume><fpage>657</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">8255963</pub-id></element-citation></ref><ref id="B34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>PR</given-names></name><name><surname>Cooper</surname><given-names>JM</given-names></name><name><surname>Govan</surname><given-names>GG</given-names></name><name><surname>Harding</surname><given-names>AE</given-names></name><name><surname>Schapira</surname><given-names>AH</given-names></name></person-group><article-title>Platelet mitochondrial function in Leber's hereditary optic neuropathy</article-title><source>J Neurol Sci</source><year>1994</year><volume>122</volume><fpage>80</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">8195807</pub-id></element-citation></ref><ref id="B35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spruijt</surname><given-names>L</given-names></name><name><surname>Kolbach</surname><given-names>DN</given-names></name><name><surname>de Coo</surname><given-names>RF</given-names></name><name><surname>Plomp</surname><given-names>AS</given-names></name><name><surname>Bauer</surname><given-names>NJ</given-names></name><name><surname>Smeets</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Influence of mutation type on clinical expression of Leber hereditary optic neuropathy</article-title><source>Am J Ophthalmol</source><year>2006</year><volume>141</volume><fpage>676</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">16564802</pub-id></element-citation></ref><ref id="B36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>D</given-names></name><name><surname>Goerlitz</surname><given-names>DS</given-names></name><name><surname>Dumitrescu</surname><given-names>RG</given-names></name><name><surname>Han</surname><given-names>D</given-names></name><name><surname>Seillier-Moiseiwitsch</surname><given-names>F</given-names></name><name><surname>Spernak</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Associations between cigarette smoking and mitochondrial DNA abnormalities in buccal cells</article-title><source>Carcinogenesis</source><year>2008</year><volume>29</volume><fpage>1170</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">18281252</pub-id></element-citation></ref><ref id="B37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsao</surname><given-names>K</given-names></name><name><surname>Aitken</surname><given-names>PA</given-names></name><name><surname>Johns</surname><given-names>DR</given-names></name></person-group><article-title>Smoking as an aetiological factor in a pedigree with Leber's hereditary optic neuropathy</article-title><source>Br J Ophthalmol</source><year>1999</year><volume>83</volume><fpage>577</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">10216058</pub-id></element-citation></ref><ref id="B38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Jaarsveld</surname><given-names>H</given-names></name><name><surname>Kuyl</surname><given-names>JM</given-names></name><name><surname>Alberts</surname><given-names>DW</given-names></name></person-group><article-title>Exposure of rats to low concentrations of cigarette smoke increases myocardial sensitivity to ischaemia/reperfusion</article-title><source>Basic Res Cardiol</source><year>1992</year><volume>87</volume><fpage>393</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">1417708</pub-id></element-citation></ref><ref id="B39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu-Wai-Man</surname><given-names>P</given-names></name><name><surname>Griffiths</surname><given-names>PG</given-names></name><name><surname>Hudson</surname><given-names>G</given-names></name><name><surname>Chinnery</surname><given-names>PF</given-names></name></person-group><article-title>Inherited mitochondrial optic neuropathies</article-title><source>J Med Genet</source><year>2009</year><volume>46</volume><fpage>145</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">19001017</pub-id></element-citation></ref></ref-list></back></article>